nach oben

Current Treatment Options in Gastroenterology

Erschienen in:

17.07.2020 | Hot Topic

Update on the Management of Helicobacter pylori Infection

verfasst von: Nasir Saleem, Colin W. Howden

Erschienen in: Current Treatment Options in Gastroenterology | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose of review

Our purpose was to provide an update on methods and indications for testing and treatment selection focusing on novel modalities.

Recent findings

Increasing antibiotic resistance has reduced treatment effectiveness. Antibiotic resistance testing is not widely available in North America where there are insufficient resistance and susceptibility data. Quadruple regimens (bismuth-based or concomitant/non-bismuth-based) have been recommended first-line. A rifabutin-based combination product recently approved by the US Food and Drug Administration is highly effective and should simplify treatment. The potassium-competitive acid blocker vonoprazan is being evaluated as part of dual or triple combination regimens. Molecular-based genotypic testing for antibiotic resistance and an effective H. pylori vaccine remain under development.

Summary

Inability to test for antibiotic resistance renders treatment selection empiric. However, resistance to rifabutin and amoxicillin remains rare. Effective management continues to comprise appropriate diagnostic testing for active infection, utilization of an effective regimen, and post-treatment testing.

Hooi JKY, Lai WY, Ng WK, Suen MMY, Underwood FE, Tanyingoh D, et al. Global prevalence of helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology. 2017;153(2):420–9. https://doi.org/10.1053/j.gastro.2017.04.022.PubMedCrossRef

Eusebi LH, Zagari RM, Bazzoli F. Epidemiology of helicobacter pylori infection. Helicobacter. 2014;19(Suppl 1):1–5. https://doi.org/10.1111/hel.12165.PubMedCrossRef

• Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol. 2017;112(2):212–39. https://doi.org/10.1038/ajg.2016.563 The most recent treatment guideline for US practice.CrossRef

Nguyen T, Ramsey D, Graham D, Shaib Y, Shiota S, Velez M, et al. The prevalence of helicobacter pylori remains high in African American and Hispanic veterans. Helicobacter. 2015;20(4):305–15. https://doi.org/10.1111/hel.12199.PubMedCrossRef

Everhart JE, Kruszon-Moran D, Perez-Perez GI, Tralka TS, McQuillan G. Seroprevalence and ethnic differences in helicobacter pylori infection among adults in the United States. J Infect Dis. 2000;181(4):1359–63. https://doi.org/10.1086/315384.PubMedCrossRef

Epplein M, Cohen SS, Sonderman JS, Zheng W, Williams SM, Blot WJ, et al. Neighborhood socio-economic characteristics, African ancestry, and Helicobacter pylori sero-prevalence. Cancer Causes Control. 2012;23(6):897–906. https://doi.org/10.1007/s10552-012-9960-7.PubMedPubMedCentralCrossRef

Grad YH, Lipsitch M, Aiello AE. Secular trends in helicobacter pylori seroprevalence in adults in the United States: evidence for sustained race/ethnic disparities. Am J Epidemiol. 2012;175(1):54–9. https://doi.org/10.1093/aje/kwr288.PubMedCrossRef

Dong E, Duan L, Wu BU. Racial and ethnic minorities at increased risk for gastric cancer in a regional US population study. Clin Gastroenterol Hepatol. 2017;15(4):511–7. https://doi.org/10.1016/j.cgh.2016.11.033.PubMedCrossRef

Fallone CA, Chiba N, van Zanten SV, Fischbach L, Gisbert JP, Hunt RH, et al. The Toronto consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology. 2016;151(1):51–69 e14. https://doi.org/10.1053/j.gastro.2016.04.006.PubMedCrossRef

10.

Sugano K, Tack J, Kuipers EJ, Graham DY, El-Omar EM, Miura S, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64(9):1353–67. https://doi.org/10.1136/gutjnl-2015-309252.PubMedPubMedCentralCrossRef

11.

Wang AY, Peura DA. The prevalence and incidence of Helicobacter pylori-associated peptic ulcer disease and upper gastrointestinal bleeding throughout the world. Gastrointest Endosc Clin N Am. 2011;21(4):613–35. https://doi.org/10.1016/j.giec.2011.07.011.PubMedCrossRef

12.

•Malfertheiner P, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT, et al. Management of Helicobacter pylori infection-the Maastricht V/florence consensus report. Gut. 2017;66(1):6–30. https://doi.org/10.1136/gutjnl-2016-312288 The most recent European guideline and recommendations related to H. pylori infection.

13.

Hunt R, Fallone C, Veldhuyzan van Zanten S, Sherman P, Smaill F, Flook N, et al. Canadian Helicobacter study group consensus conference: update on the management of Helicobacter pylori--an evidence-based evaluation of six topics relevant to clinical outcomes in patients evaluated for H pylori infection. Can J Gastroenterol. 2004;18(9):547–54. https://doi.org/10.1155/2004/326767.PubMedCrossRef

14.••

Ford AC, Yuan Y, Moayyedi P. Helicobacter pylori eradication therapy to prevent gastric cancer: systematic review and meta-analysis. Gut 2020; in press Recently updated systeamtic review and meta-analysis of trials showing a reduced risk of gastric cancer through treatment of H. pylori infection in asymptomatic individuals and also confirming the benefit of eradication of H. pylori infection in patients following endoscopic resection of early gastric neoplastic lesions.

15.

• Moayyedi P, Lacy BE, Andrews CN, Enns RA, Howden CW, Vakil N. ACG and CAG clinical guideline: management of dyspepsia. Am J Gastroenterol. 2017;112(7):988–1013. https://doi.org/10.1038/ajg.2017.154 US/Canadian joint guideline on the management of dyspepsia including discussion of role of testing for and treating H. pylori infection in uninvestigated dyspepsia and functional dyspepsia.CrossRef

16.

Chiba N, Van Zanten SJ, Sinclair P, Ferguson RA, Escobedo S, Grace E. Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatment-helicobacter pylori positive (CADET-Hp) randomised controlled trial. BMJ. 2002;324(7344):1012–6. https://doi.org/10.1136/bmj.324.7344.1012.PubMedPubMedCentralCrossRef

17.

•• Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E. Prevalence of antibiotic resistance in Helicobacter pylori: a systematic review and meta-analysis in World Health Organization regions. Gastroenterology. 2018;155(5):1372–82 e17. https://doi.org/10.1053/j.gastro.2018.07.007 Some of the most recent data on antimicrobial resistance rates amongH. pylori strains geographically.

18.

Lahaie RG, Gaudreau C. Helicobacter pylori antibiotic resistance: trends over time. Can J Gastroenterol. 2000;14(10):895–9. https://doi.org/10.1155/2000/218256.PubMedCrossRef

19.

Saad RJ, Chey WD. Persistent Helicobacter pylori infection after a course of antimicrobial therapy-what’s next? Clin Gastroenterol Hepatol. 2008;6(10):1086–90. https://doi.org/10.1016/j.cgh.2008.05.009.PubMedCrossRef

20.

Megraud F, Coenen S, Versporten A, Kist M, Lopez-Brea M, Hirschl AM, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut. 2013;62(1):34–42. https://doi.org/10.1136/gutjnl-2012-302254.PubMedCrossRef

21.

McMahon BJ, Hennessy TW, Bensler JM, Bruden DL, Parkinson AJ, Morris JM, et al. The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for helicobacter pylori infections. Ann Intern Med. 2003;139(6):463–9. https://doi.org/10.7326/0003-4819-139-6-200309160-00008.PubMedCrossRef

22.

•• Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18(3):318–27. https://doi.org/10.1016/S1473-3099(17)30753-3 The WHO’s position on priorities for development of newer agents for resistant bacterial infections including H. pylori.PubMedCrossRef

23.

Fallone CA, Moss SF, Malfertheiner P. Reconciliation of recent Helicobacter pylori treatment guidelines in a time of increasing resistance to antibiotics. Gastroenterology. 2019;157(1):44–53. https://doi.org/10.1053/j.gastro.2019.04.011.PubMedCrossRef

24.

Nishizawa T, Suzuki H. Mechanisms of Helicobacter pylori antibiotic resistance and molecular testing. Front Mol Biosci. 2014;1:19. https://doi.org/10.3389/fmolb.2014.00019.PubMedPubMedCentralCrossRef

25.

Plummer M, Franceschi S, Vignat J, Forman D, de Martel C. Global burden of gastric cancer attributable to Helicobacter pylori. Int J Cancer. 2015;136(2):487–90. https://doi.org/10.1002/ijc.28999.CrossRef

26.•

de Martel C, Georges D, Bray F, Ferlay J, Clifford GM. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health. 2019. https://doi.org/10.1016/S2214-109X(19)30488-7 Interesting perspective that H. pylori is responsible for more cancers worldwide than HPV, HBV, or HCV.

27.

•• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. https://doi.org/10.3322/caac.21590 Official estimates from American Cancer Society about new diagnoses of, and deaths from, various cancers in the USA for 2020; more new cases of gastric cancer than both types of esophageal cancer combined are predicted for 2020.CrossRef

28.••

Kumar S, Metz DC, Ellenberg S, Kaplan DE, Goldberg DS. Risk factors and incidence of gastric cancer after detection of Helicobacter pylori infection: a large cohort studyGastroenterology. 2019. https://doi.org/10.1053/j.gastro.2019.10.019 Evidence from a US-based study that eradication of H. pylori in asymptomatic adults reduces lifetime risk of gastric cancer.

29.

Lee YC, Chiang TH, Chou CK, Tu YK, Liao WC, Wu MS, et al. Association between Helicobacter pylori eradication and gastric CANCER incidence: a systematic review and meta-analysis. Gastroenterology. 2016;150(5):1113–24 e5. https://doi.org/10.1053/j.gastro.2016.01.028.PubMedCrossRef

30.

•• Choi IJ, Kim CG, Lee JY, Kim YI, Kook MC, Park B, et al. Family history of gastric cancer and Helicobacter pylori treatment. N Engl J Med. 2020;382(5):427–36. https://doi.org/10.1056/NEJMoa1909666 Important study from South Korea demonstrating that infected first-degree relatives of gastric cancer patients benefit from treatment for H. pylori infection.PubMedCrossRef

31.

El-Serag HB, Kao JY, Kanwal F, Gilger M, LoVecchio F, Moss SF, et al. Houston consensus conference on testing for Helicobacter pylori infection in the United States. Clin Gastroenterol Hepatol. 2018;16(7):992–1002 e6. https://doi.org/10.1016/j.cgh.2018.03.013.PubMedPubMedCentralCrossRef

32.

Lee YC, Chiang TH, Liou JM, Chen HH, Wu MS, Graham DY. Mass eradication of Helicobacter pylorito prevent gastric cancer: theoretical and practical considerations. Gut Liver. 2016;10(1):12–26. https://doi.org/10.5009/gnl15091.PubMedPubMedCentralCrossRef

33.

Asaka M, Mabe K, Matsushima R, Tsuda M. Helicobacter pylori eradication to eliminate gastric cancer: the Japanese strategy. Gastroenterol Clin N Am. 2015;44(3):639–48. https://doi.org/10.1016/j.gtc.2015.05.010.CrossRef

34.••

Gupta S, Li D, El Serag HB, Davitkov P, Altayar O, Sultan S, et al. AGA clinical practice guidelines on management of gastric intestinal metaplasia. Gastroenterology. 2019. https://doi.org/10.1053/j.gastro.2019.12.003 American Gastroenterological Association’s recommendations for management of gastric intestinal metaplasia.

35.

Neunert C, Terrell DR, Arnold DM, Buchanan G, Cines DB, Cooper N, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829–66. https://doi.org/10.1182/bloodadvances.2019000966.PubMedPubMedCentralCrossRef

36.

Siddique O, Ovalle A, Siddique AS, Moss SF. Helicobacter pylori infection: an update for the internist in the age of increasing global antibiotic resistance. Am J Med. 2018;131(5):473–9. https://doi.org/10.1016/j.amjmed.2017.12.024.PubMedCrossRef

37.

Howden CW, Blume SW, de Lissovoy G. Practice patterns for managing Helicobacter pylori infection and upper gastrointestinal symptoms. Am J Manag Care. 2007;13(1):37–44.PubMed

38.

Theel ES, Johnson RD, Plumhoff E, Hanson CA. Use of the Optum Labs Data Warehouse to assess test ordering patterns for diagnosis of Helicobacter pylori infection in the United States. J Clin Microbiol. 2015;53(4):1358–60. https://doi.org/10.1128/JCM.03464-14.PubMedPubMedCentralCrossRef

39.

Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney system. International workshop on the histopathology of gastritis, Houston 1994. Am J Surg Pathol. 1996;20(10):1161–81. https://doi.org/10.1097/00000478-199610000-00001.PubMedCrossRef

40.

Uotani T, Graham DY. Diagnosis of Helicobacter pylori using the rapid urease test. Ann Transl Med. 2015;3(1):9. https://doi.org/10.3978/j.issn.2305-5839.2014.12.04.PubMedPubMedCentralCrossRef

41.

Choi YJ, Kim N, Lim J, Jo SY, Shin CM, Lee HS, et al. Accuracy of diagnostic tests for Helicobacter pylori in patients with peptic ulcer bleeding. Helicobacter. 2012;17(2):77–85. https://doi.org/10.1111/j.1523-5378.2011.00915.x.PubMedCrossRef

42.

Megraud F, Lehours P. Helicobacter pylori detection and antimicrobial susceptibility testing. Clin Microbiol Rev. 2007;20(2):280–322. https://doi.org/10.1128/CMR.00033-06.PubMedPubMedCentralCrossRef

43.

Wenzhen Y, Yumin L, Quanlin G, Kehu Y, Lei J, Donghai W, et al. Is antimicrobial susceptibility testing necessary before first-line treatment for Helicobacter pylori infection? Meta-analysis of randomized controlled trials. Intern Med. 2010;49(12):1103–9. https://doi.org/10.2169/internalmedicine.49.3031.PubMedCrossRef

44.

Lopez-Gongora S, Puig I, Calvet X, Villoria A, Baylina M, Munoz N, et al. Systematic review and meta-analysis: susceptibility-guided versus empirical antibiotic treatment for Helicobacter pylori infection. J Antimicrob Chemother. 2015;70(9):2447–55. https://doi.org/10.1093/jac/dkv155.PubMedCrossRef

45.

Shiota S, Reddy R, Alsarraj A, El-Serag HB, Graham DY. Antibiotic resistance of Helicobacter pylori among male United States Veterans. Clin Gastroenterol Hepatol. 2015;13(9):1616–24. https://doi.org/10.1016/j.cgh.2015.02.005.PubMedPubMedCentralCrossRef

46.

Duck WM, Sobel J, Pruckler JM, Song Q, Swerdlow D, Friedman C, et al. Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons, United States. Emerg Infect Dis. 2004;10(6):1088–94. https://doi.org/10.3201/eid1006.030744.PubMedPubMedCentralCrossRef

47.

Bordin DS, Yanova OB, Abdulkhakov RA, Tsukanov VV, Livzan MA, Burkov SG, et al. European Registry on the management of Helicobacter pylori infection (Hp-EuReg protocol): the first results of Russian centers. Ter Arkh. 2016;88(2):33–8. https://doi.org/10.17116/terarkh201688233-38.PubMedCrossRef

48.

Beckman E, Saracino I, Fiorini G, Clark C, Slepnev V, Patel D, et al. A novel stool PCR test for Helicobacter pylori may predict clarithromycin resistance and eradication of infection at a high rate. J Clin Microbiol. 2017;55(8):2400–5. https://doi.org/10.1128/JCM.00506-17.PubMedPubMedCentralCrossRef

49.

Iannone A, Giorgio F, Russo F, Riezzo G, Girardi B, Pricci M, et al. New fecal test for non-invasive Helicobacter pylori detection: a diagnostic accuracy study. World J Gastroenterol. 2018;24(27):3021–9. https://doi.org/10.3748/wjg.v24.i27.3021.PubMedPubMedCentralCrossRef

50.

• Alsamman MA, Vecchio EC, Shawwa K, Acosta-Gonzales G, Resnick MB, Moss SF. Retrospective analysis confirms tetracycline quadruple as best Helicobacter pylori regimen in the USA. Dig Dis Sci. 2019;64(10):2893–8. https://doi.org/10.1007/s10620-019-05694-4 The most recent “real world” data from the USA about the performance of some widely prescribed combination regimens for H. pylori infection.PubMedCrossRef

51.

• McNicholl AG, Bordin DS, Lucendo A, Fadeenko G, Fernandez MC, Voynovan I, et al. Combination of bismuth and standard triple therapy eradicates Helicobacter pylori infection in more than 90% of patients. Clin Gastroenterol Hepatol. 2020;18(1):89–98. https://doi.org/10.1016/j.cgh.2019.03.048 Evidence that the simple addition of bismuth to a combination regimen may boost eradication rates.PubMedCrossRef

52.

• Castells M, Khan DA, Phillips EJ. Penicillin allergy. N Engl J Med. 2019;381(24):2338–51. https://doi.org/10.1056/NEJMra1807761 Important and authoritative review of the problem of penicillin allergy with reliable estimates of its true prevalence.PubMedCrossRef

53.

Yang JC, Lin CJ, Wang HL, Chen JD, Kao JY, Shun CT, et al. High-dose dual therapy is superior to standard first-line or rescue therapy for Helicobacter pylori infection. Clin Gastroenterol Hepatol. 2015;13(5):895–905 e5. https://doi.org/10.1016/j.cgh.2014.10.036.PubMedCrossRef

54.

Gisbert JP, Calvet X. Review article: rifabutin in the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther. 2012;35(2):209–21. https://doi.org/10.1111/j.1365-2036.2011.04937.x.PubMedCrossRef

55.

Chen Q, Long X, Ji Y, Liang X, Li D, Gao H, et al. Randomised controlled trial: susceptibility-guided therapy versus empiric bismuth quadruple therapy for first-line Helicobacter pylori treatment. Aliment Pharmacol Ther. 2019;49(11):1385–94. https://doi.org/10.1111/apt.15273.PubMedCrossRef

56.

Yang X, Wang JX, Han SX, Gao CP. High dose dual therapy versus bismuth quadruple therapy for Helicobacter pylori eradication treatment: a systematic review and meta-analysis. Medicine (Baltimore). 2019;98(7):e14396. https://doi.org/10.1097/MD.0000000000014396.CrossRef

57.

Labenz J. Current role of acid suppressants in helicobacter pylori eradication therapy. Best Pract Res Clin Gastroenterol. 2001;15(3):413–31. https://doi.org/10.1053/bega.2001.0188.PubMedCrossRef

58.

Miehlke S, Kirsch C, Schneider-Brachert W, Haferland C, Neumeyer M, Bastlein E, et al. A prospective, randomized study of quadruple therapy and high-dose dual therapy for treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. Helicobacter. 2003;8(4):310–9. https://doi.org/10.1046/j.1523-5378.2003.00158.x.PubMedCrossRef

59•.

Graham DY, Canaan Y, Maher J, et al. Rifabutin-based triple therapy (RHB-105) for Helicobacter pylori eradication: A double-blind, randomized, controlled trial. Ann Intern Med 2020;172:795–802. Publication of the randomized controlled trial of the rifabutin-amoxicillin-omeprazole combination product that was approved by the FDA in late 2019.

60.

Pasala C, Chilamakuri CSR, Katari SK, Nalamolu RM, Bitla AR, Umamaheswari A. An in silico study: novel targets for potential drug and vaccine design against drug resistant H. pylori. Microb Pathog. 2018;122:156–61. https://doi.org/10.1016/j.micpath.2018.05.037.PubMedCrossRef

61.

Nelson R. Antibiotic development pipeline runs dry. New drugs to fight resistant organisms are not being developed, experts say. Lancet. 2003;362(9397):1726–7. https://doi.org/10.1016/s0140-6736(03)14885-4.PubMedPubMedCentralCrossRef

62.

Ohkuma K, Iida H, Inoh Y, Kanoshima K, Ohkubo H, Nonaka T, et al. Comparison of the early effects of vonoprazan, lansoprazole and famotidine on intragastric pH: a three-way crossover study. J Clin Biochem Nutr. 2018;63(1):80–3. https://doi.org/10.3164/jcbn.17-128.PubMedPubMedCentralCrossRef

63.

• Jung YS, Kim EH, Park CH. Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication. Aliment Pharmacol Ther. 2017;46(2):106–14. https://doi.org/10.1111/apt.14130 Evidence from Asian studies of the efficacy of the P-CAB vonoprazan as part of combination regimens against H. pylori.PubMedCrossRef

64.

Furuta T, Yamade M, Kagami T, Uotani T, Suzuki T, Higuchi T, Tani S, Hamaya Y, Iwaizumi M, Miyajima H, Umemura K, Osawa S, Sugimoto K Dual therapy with vonoprazan and amoxicillin is as effective as triple therapy with vonoprazan, amoxicillin and clarithromycin for eradication of Helicobacter pylori. Digestion. 2019:1–9. doi:https://doi.org/10.1159/000502287.

65.

Suzuki S, Gotoda T, Kusano C, Ikehara H, Ichijima R, Ohyauchi M, et al. Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan. Gut. 2020;69:1019–26. https://doi.org/10.1136/gutjnl-2019-319954.PubMedPubMedCentralCrossRef

66.

Graham DY, Dore MP. Update on the use of vonoprazan: a competitive acid blocker. Gastroenterology. 2018;154(3):462–6. https://doi.org/10.1053/j.gastro.2018.01.018.PubMedCrossRef

67.

Scarpignato C, Hunt RH. Editorial: potassium-competitive acid blockers for acid-related diseases-tegoprazan, a new kid on the block. Aliment Pharmacol Ther. 2019;50(8):960–2. https://doi.org/10.1111/apt.15480.PubMedCrossRef

68.

Graham DY, Tansel A. Interchangeable use of proton pump inhibitors based on relative potency. Clin Gastroenterol Hepatol. 2018;16(6):800–8 e7. https://doi.org/10.1016/j.cgh.2017.09.033.PubMedCrossRef

69.

McFarland LV, Huang Y, Wang L, Malfertheiner P. Systematic review and meta-analysis: multi-strain probiotics as adjunct therapy for Helicobacter pylori eradication and prevention of adverse events. United Eur Gastroenterol J. 2016;4(4):546–61. https://doi.org/10.1177/2050640615617358.CrossRef

70.

Wang ZH, Gao QY, Fang JY. Meta-analysis of the efficacy and safety of lactobacillus-containing and bifidobacterium-containing probiotic compound preparation in Helicobacter pylori eradication therapy. J Clin Gastroenterol. 2013;47(1):25–32. https://doi.org/10.1097/MCG.0b013e318266f6cf.PubMedCrossRef

71.

Zhang S, Moise L, Moss SF. H. pylori vaccines: why we still don’t have any. Hum Vaccin. 2011;7(11):1153–7. https://doi.org/10.4161/hv.7.11.17655.PubMedPubMedCentralCrossRef

72.

Zeng M, Mao XH, Li JX, Tong WD, Wang B, Zhang YJ, et al. Efficacy, safety, and immunogenicity of an oral recombinant Helicobacter pylori vaccine in children in China: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386(10002):1457–64. https://doi.org/10.1016/S0140-6736(15)60310-5.PubMedCrossRef

Titel: Update on the Management of Helicobacter pylori Infection
verfasst von: Nasir Saleem
Colin W. Howden
Publikationsdatum: 17.07.2020
Verlag: Springer US
Erschienen in: Current Treatment Options in Gastroenterology / Ausgabe 3/2020
Print ISSN: 1092-8472
Elektronische ISSN: 1534-309X
DOI: https://doi.org/10.1007/s11938-020-00300-3

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

19.04.2024 | Vorhofflimmern | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Update on the Management of Helicobacter pylori Infection

Abstract

Purpose of review

Recent findings

Summary

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose of review

Recent findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2020

Update on Pregnancy in Patients with IBD

Inflammatory Bowel Disease Therapy and Venous Thromboembolism

Gastritis: An Update in 2020

Enteric Hyperoxaluria and Kidney Stone Management in Inflammatory Bowel Disease

7RECENT Advances in Endoscopic Treatments for Gastroesophageal Reflux Disease

What Is the Optimal Surveillance Strategy for Non-dysplastic Barrett’s Esophagus?

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin